Growing community of inventors

Waterloo, Canada

John Gerard Flanagan

Average Co-Inventor Count = 7.72

ph-index = 1

The patent ph-index is calculated by counting the number of publications for which an author has been cited by other authors at least that same number of times.

Forward Citations = 2

John Gerard FlanaganJohn E Thompson (3 patents)John Gerard FlanaganCatherine Taylor (3 patents)John Gerard FlanaganElizabeth Heikkila (3 patents)John Gerard FlanaganDominic O Cliche (2 patents)John Gerard FlanaganBruce C Galton (2 patents)John Gerard FlanaganAdrienne Boone (2 patents)John Gerard FlanaganShelley Culp-Stewart (2 patents)John Gerard FlanaganMichelle Senchyna (2 patents)John Gerard FlanaganDominic Cliché (1 patent)John Gerard FlanaganDiane Michelle Senchyna (1 patent)John Gerard FlanaganDiana Michelle Senchyna (0 patent)John Gerard FlanaganElisabeth M Heikkila (0 patent)John Gerard FlanaganJohn Gerard Flanagan (3 patents)John E ThompsonJohn E Thompson (32 patents)Catherine TaylorCatherine Taylor (11 patents)Elizabeth HeikkilaElizabeth Heikkila (3 patents)Dominic O ClicheDominic O Cliche (6 patents)Bruce C GaltonBruce C Galton (3 patents)Adrienne BooneAdrienne Boone (3 patents)Shelley Culp-StewartShelley Culp-Stewart (2 patents)Michelle SenchynaMichelle Senchyna (2 patents)Dominic ClichéDominic Cliché (1 patent)Diane Michelle SenchynaDiane Michelle Senchyna (1 patent)Diana Michelle SenchynaDiana Michelle Senchyna (0 patent)Elisabeth M HeikkilaElisabeth M Heikkila (0 patent)
..
Inventor’s number of patents
..
Strength of working relationships

Company Filing History:

1. Senesco Technologies, Inc. (2 from 16 patents)

2. Sensco Technologies, Inc. (1 from 1 patent)


3 patents:

1. 8242256 - siRNA useful to supress expression of EIF-5A1

2. 7662796 - Use of antisense oligonucleotides or siRNA to suppress expression of eIF-5A1

3. 7381708 - Suppression of eIF5A1 expression by the use of antisense oligonucleotides for the prevention of retinal cell death in the glaucomatous eye

Please report any incorrect information to support@idiyas.com
idiyas.com
as of
12/12/2025
Loading…